Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04230304
Title Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic

chronic lymphocytic leukemia/small lymphocytic lymphoma

chronic lymphocytic leukemia


Daratumumab + Ibrutinib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.